The FDA has granted Zogenix a Breakthrough Therapy Designation for its pipeline product, ZX008 for the treatment of seizures associated with Dravet syndrome.
The MHRA's chief executive accompanied the Prime Minister to Beijing this week, and signed a new memorandum of understanding (MoU) with Chinese counterparts.
